In September, our Linked Clinical Trials committee met for the sixth year running - a pioneering collaborative meeting of many of the world's leading Parkinson's authorities, to discuss fast tracking potential drugs for repurposing in Parkinson's ... Read more

In August, CPT was delighted to announce that the R S MacDonald Charitable Trust awarded a grant to co-fund the continuing dopamine replacement stem cell research of Dr Tilo Kunath in Edinburgh... Read more

The CPT Advent

Welcome to our Christmas Advent.

Every day we will look back over 2018 and celebrate some key events in the run up to Christmas day. This has been a year of collaborations and progress - and our determination to discover therapies to slow, stop or even reverse Parkinson's remains resolute.

We are grateful to every one for your continuing support of our missionand we wish you a very Happy Christmas and a fulfilling 2019.

In September, our Linked Clinical Trials committee met for the sixth year running - a pioneering collaborative meeting of many of the world's leading Parkinson's authorities, to discuss fast tracking potential drugs for repurposing in Parkinson's ...Read more

In August, CPT was delighted to announce that the R S MacDonald Charitable Trust awarded a grant to co-fund the continuing dopamine replacement stem cell research of Dr Tilo Kunath in Edinburgh...Read more

In July we reported on Johns Hopkins researchers who had shown that the experimental drug NLY01 had blocked the degradation of neurons - a hallmark of Parkinson's. The drug is now expected to move to swiftly into clinical trials...Read more

A shift in the dominant view on Parkinson’s is taking place, with leading clinicians and researchers around the world recognising that a ‘one size fits all’ approach is not serving people with Parkinson’s in the quest for cures. In April we discussed precision medicine in Parkinson's...Read more

Understanding the underlying causes of Parkinson's is becoming an invaluable route to the discovery of new and promising treatments. Several studies have suggested that people who are diabetic may be more likely to be diagnosed with Parkinson’s at some point in their lifetime...Read more

This year we have seen individual fundraisers take on all sorts of interesting and challenging fundraising activities in support of CPT. We’ll be looking back on their amazing achievements over the year, so here’s a few to start us off...Read more

Early in 2018 Trustees approved funding for a new technique which uses a person with Parkinson's own skin cells to grow neurons affected by their particular type of the disease to then treat with certain drugs.Read more

Latest

Researchers at the Michael J Fox Foundation recently announced that SURE-PD3, a Phase III clinical trial evaluating the potential of Inosine to slow Parkinson's progression, will end earlier than planned...

Most read

In a major breakthrough for the treatment of Parkinson's, researchers working with laboratory rats show it is possible to make dopamine cells from embryonic stem cells and transplant them into the brain.

Our international Linked Clinical Trials initiative (LCT) identifies potential new treatments to slow, stop or reverse Parkinson’s disease by 'repurposing' or repositioning drugs that are approved to treat other conditions.

When diagnosed, people with Parkinson’s have often had the disease for years and have lost over half of the dopamine producing cells in their brain. Now scientists are searching for a way to replace these nerve cells.

The study, published in The Lancet and funded by The Michael J. Fox Foundation for Parkinson’s Research (MJFF), supported by CPT found that people with Parkinson’s treated with Exenatide for one year performed better in motor tests than those on placebo.